BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...Therapeutics Inc. (NASDAQ:INSY) ü Triptans Axert almotriptan Almirall S.A. (Madrid:ALM)/Johnson & Johnson (NYSE:JNJ) ü Frova frovatriptan...
BioCentury | Feb 3, 2014
Company News

Endo, Mylan neurology news

...valid, and that an ANDA from Mylan for a generic version of migraine drug Frova frovatriptan...
...frovatriptan infringes on the patent. Endo said the decision prevents Mylan from marketing its generic Frova...
...waived the claims during the trial. Endo filed suit in the court in August 2011. Frova...
BioCentury | Aug 22, 2011
Company News

Endo, Mylan neurology news

...Pharmaceuticals Inc. subsidiary alleging that an ANDA for a generic version of migraine drug Frova frovatriptan...
...manufacturing or import of any generic version of Frova. Endo has North American rights to frovatriptan...
...Co. Ltd. (Seoul, South Korea) markets frovatriptan in South Korea. Endo recorded $27.4 million in Frova...
BioCentury | Aug 15, 2011
Clinical News

Frova regulatory update

...Vernalis disclosed in its 1H11 earnings that Russia approved frovatriptan to treat migraine. Menarini Group (Florence...
...frovatriptan as Frova in North America, while SK Chemicals Co. Ltd. (Seoul, South Korea) markets frovatriptan...
...Ford, Pa. Vernalis plc (LSE:VER), Winnersh, U.K. Product: Frova ( Migard - EU) frovatriptan ( EN3266...
BioCentury | Mar 15, 2010
Company News

Vernalis, Paul Capital Partners deal

...Vernalis completed its previously announced reacquisition of the frovatriptan royalty stream for the acute treatment of...
BioCentury | Mar 2, 2010
Financial News

Vernalis raises L30 million

...Paul Capital Partners' Paul Capital Healthcare to regain full rights to the royalty stream for frovatriptan...
...frovatriptan in Europe and Central America. The selective serotonin (5-HT1B/1D) receptor agonist is marketed as Migard...
BioCentury | Feb 15, 2010
Company News

Vernalis, Paul Capital Partners deal

...Vernalis will repurchase full rights to the royalty stream for frovatriptan from Paul Capital's Paul Capital...
...of the royalties Vernalis receives from Menarini Group (Florence, Italy) under a licensing deal for frovatriptan...
...€32.4 million ($44.4 million) for frovatriptan. The selective serotonin (5-HT1B/1D) receptor agonist is marketed as Migard...
BioCentury | Feb 12, 2010
Financial News

Vernalis planning offering, repurchase of frovatriptan royalties

...Paul Capital Partners' Paul Capital Healthcare to regain full rights to the royalty stream for frovatriptan...
...of the royalties Vernalis receives from Menarini Group (Florence, Italy) under a licensing deal for frovatriptan...
...on net sales to Vernalis, reported 2009 sales of EUR 32.4 million ($44.4 million) for frovatriptan...
BioCentury | Jun 8, 2009
Clinical News

Frova frovatriptan regulatory update

...Ford, Pa. Vernalis plc (LSE:VER), Winnersh, U.K. Product: Frova frovatriptan ( Migard - EU) ( EN3266...
...EU) ( EN3266 ) Business: Neurology Vernalis said South Korea granted marketing approval for frovatriptan...
...Korea). Frovatriptan is a selective serotonin (5HT1B/1D) receptor agonist. Vernalis and Endo co-promote frovatriptan as Frova...
BioCentury | Dec 8, 2008
Clinical News

VML 251 5HTIB/1D agonist data

Full results of a Phase IIb trial of VML 251 in 1000 patients show long half-life with a low rate of headache recurrence. As reported at the Congress of the International Headache Society in Amsterdam,...
Items per page:
1 - 10 of 181